This company listing is no longer active
2GT Stock Overview
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Applied Genetic Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.34 |
| 52 Week High | €1.95 |
| 52 Week Low | €0.23 |
| Beta | 1.58 |
| 1 Month Change | -16.91% |
| 3 Month Change | -11.95% |
| 1 Year Change | -80.63% |
| 3 Year Change | -87.16% |
| 5 Year Change | -89.91% |
| Change since IPO | -96.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2GT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -0.7% | -0.3% |
| 1Y | -80.6% | 35.8% | 4.1% |
Return vs Industry: 2GT underperformed the German Biotechs industry which returned 7.4% over the past year.
Return vs Market: 2GT underperformed the German Market which returned -15.6% over the past year.
Price Volatility
| 2GT volatility | |
|---|---|
| 2GT Average Weekly Movement | 23.2% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2GT's share price has been volatile over the past 3 months.
Volatility Over Time: 2GT's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 102 | Sue Washer | https://agtc.com |
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease.
Applied Genetic Technologies Corporation Fundamentals Summary
| 2GT fundamental statistics | |
|---|---|
| Market cap | €12.62m |
| Earnings (TTM) | -€66.98m |
| Revenue (TTM) | €309.95k |
35.1x
P/S Ratio-0.2x
P/E RatioIs 2GT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2GT income statement (TTM) | |
|---|---|
| Revenue | US$325.00k |
| Cost of Revenue | US$21.76m |
| Gross Profit | -US$21.44m |
| Other Expenses | US$48.80m |
| Earnings | -US$70.23m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | -6,596.62% |
| Net Profit Margin | -21,610.46% |
| Debt/Equity Ratio | 92.6% |
How did 2GT perform over the long term?
See historical performance and comparison